The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
 
Edward B. Garon
Consulting or Advisory Role - Dracen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Nektar; Novartis; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Enric Carcereny Costa
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche; Takeda
 
Natasha B. Leighl
Research Funding - Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Pfizer; Roche; Roche/Genentech
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Alpha Pharmaceutical; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Takeda
 
Joseph Paul Eder
Consulting or Advisory Role - Roche/Genentech
 
Ani Sarkis Balmanoukian
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genentech; Lilly; MedImmune
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; Incyte; Janssen; Lilly; Merck; Tesaro; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Amita Patnaik
Consulting or Advisory Role - Bayer; Genentech/Roche (I); Merck; Novartis
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Infinity Pharmaceuticals (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Proximagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Matthew A. Gubens
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Heron; Mersana; Novartis; Takeda
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - EMD Serono (Inst); Merck (Inst)
 
Cathie Scalzo
Employment - Merck
 
Erin Jensen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Debra A. Kush
Employment - Merck
 
Rina Hui
Honoraria - Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Roche